Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis

A K M Ashiqul Haque, Alexander Dewerth, Justin S Antony, Joachim Riethmüller, Georg R Schweizer, Petra Weinmann, Ngadhnjim Latifi, Hanzey Yasar, Nicoletta Pedemonte, Elvira Sondo, Brian Weidensee, Anjali Ralhan, Julie Laval, Patrick Schlegel, Christian Seitz, Brigitta Loretz, Claus-Michael Lehr, Rupert Handgretinger, Michael S D Kormann

Research output: Contribution to journalArticle

Abstract

Gene therapy has always been a promising therapeutic approach for Cystic Fibrosis (CF). However, numerous trials using DNA or viral vectors encoding the correct protein resulted in a general low efficacy. In the last years, chemically modified messenger RNA (cmRNA) has been proven to be a highly potent, pulmonary drug. Consequently, we first explored the expression, function and immunogenicity of human (h)CFTR encoded by cmRNAhCFTR in vitro and ex vivo, quantified the expression by flow cytometry, determined its function using a YFP based assay and checked the immune response in human whole blood. Similarly, we examined the function of cmRNAhCFTR in vivo after intratracheal (i.t.) or intravenous (i.v.) injection of the assembled cmRNAhCFTR together with Chitosan-coated PLGA (poly-D, L-lactide-co-glycolide 75:25 (Resomer RG 752 H)) nanoparticles (NPs) by FlexiVent. The amount of expression of human hCFTR encoded by cmRNAhCFTR was quantified by hCFTR ELISA, and cmRNAhCFTR values were assessed by RT-qPCR. Thereby, we observed a significant improvement of lung function, especially in regards to FEV0.1, suggesting NP-cmRNAhCFTR as promising therapeutic option for CF patients independent of their CFTR genotype.

Original languageEnglish
Pages (from-to)16776
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - Nov 13 2018

Fingerprint

Cystic Fibrosis
Nanoparticles
Lung
Messenger RNA
Viral DNA
Chitosan
Intravenous Injections
Genetic Therapy
Flow Cytometry
Enzyme-Linked Immunosorbent Assay
Genotype
Therapeutics
Pharmaceutical Preparations
Proteins
polylactic acid-polyglycolic acid copolymer

Cite this

Haque, A. K. M. A., Dewerth, A., Antony, J. S., Riethmüller, J., Schweizer, G. R., Weinmann, P., ... Kormann, M. S. D. (2018). Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Scientific Reports, 8(1), 16776. https://doi.org/10.1038/s41598-018-34960-0

Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. / Haque, A K M Ashiqul; Dewerth, Alexander; Antony, Justin S; Riethmüller, Joachim; Schweizer, Georg R; Weinmann, Petra; Latifi, Ngadhnjim; Yasar, Hanzey; Pedemonte, Nicoletta; Sondo, Elvira; Weidensee, Brian; Ralhan, Anjali; Laval, Julie; Schlegel, Patrick; Seitz, Christian; Loretz, Brigitta; Lehr, Claus-Michael; Handgretinger, Rupert; Kormann, Michael S D.

In: Scientific Reports, Vol. 8, No. 1, 13.11.2018, p. 16776.

Research output: Contribution to journalArticle

Haque, AKMA, Dewerth, A, Antony, JS, Riethmüller, J, Schweizer, GR, Weinmann, P, Latifi, N, Yasar, H, Pedemonte, N, Sondo, E, Weidensee, B, Ralhan, A, Laval, J, Schlegel, P, Seitz, C, Loretz, B, Lehr, C-M, Handgretinger, R & Kormann, MSD 2018, 'Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis', Scientific Reports, vol. 8, no. 1, pp. 16776. https://doi.org/10.1038/s41598-018-34960-0
Haque AKMA, Dewerth A, Antony JS, Riethmüller J, Schweizer GR, Weinmann P et al. Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Scientific Reports. 2018 Nov 13;8(1):16776. https://doi.org/10.1038/s41598-018-34960-0
Haque, A K M Ashiqul ; Dewerth, Alexander ; Antony, Justin S ; Riethmüller, Joachim ; Schweizer, Georg R ; Weinmann, Petra ; Latifi, Ngadhnjim ; Yasar, Hanzey ; Pedemonte, Nicoletta ; Sondo, Elvira ; Weidensee, Brian ; Ralhan, Anjali ; Laval, Julie ; Schlegel, Patrick ; Seitz, Christian ; Loretz, Brigitta ; Lehr, Claus-Michael ; Handgretinger, Rupert ; Kormann, Michael S D. / Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. In: Scientific Reports. 2018 ; Vol. 8, No. 1. pp. 16776.
@article{1c32957cef5048a5929b8e4395a1dd58,
title = "Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis",
abstract = "Gene therapy has always been a promising therapeutic approach for Cystic Fibrosis (CF). However, numerous trials using DNA or viral vectors encoding the correct protein resulted in a general low efficacy. In the last years, chemically modified messenger RNA (cmRNA) has been proven to be a highly potent, pulmonary drug. Consequently, we first explored the expression, function and immunogenicity of human (h)CFTR encoded by cmRNAhCFTR in vitro and ex vivo, quantified the expression by flow cytometry, determined its function using a YFP based assay and checked the immune response in human whole blood. Similarly, we examined the function of cmRNAhCFTR in vivo after intratracheal (i.t.) or intravenous (i.v.) injection of the assembled cmRNAhCFTR together with Chitosan-coated PLGA (poly-D, L-lactide-co-glycolide 75:25 (Resomer RG 752 H)) nanoparticles (NPs) by FlexiVent. The amount of expression of human hCFTR encoded by cmRNAhCFTR was quantified by hCFTR ELISA, and cmRNAhCFTR values were assessed by RT-qPCR. Thereby, we observed a significant improvement of lung function, especially in regards to FEV0.1, suggesting NP-cmRNAhCFTR as promising therapeutic option for CF patients independent of their CFTR genotype.",
author = "Haque, {A K M Ashiqul} and Alexander Dewerth and Antony, {Justin S} and Joachim Riethm{\"u}ller and Schweizer, {Georg R} and Petra Weinmann and Ngadhnjim Latifi and Hanzey Yasar and Nicoletta Pedemonte and Elvira Sondo and Brian Weidensee and Anjali Ralhan and Julie Laval and Patrick Schlegel and Christian Seitz and Brigitta Loretz and Claus-Michael Lehr and Rupert Handgretinger and Kormann, {Michael S D}",
year = "2018",
month = "11",
day = "13",
doi = "10.1038/s41598-018-34960-0",
language = "English",
volume = "8",
pages = "16776",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis

AU - Haque, A K M Ashiqul

AU - Dewerth, Alexander

AU - Antony, Justin S

AU - Riethmüller, Joachim

AU - Schweizer, Georg R

AU - Weinmann, Petra

AU - Latifi, Ngadhnjim

AU - Yasar, Hanzey

AU - Pedemonte, Nicoletta

AU - Sondo, Elvira

AU - Weidensee, Brian

AU - Ralhan, Anjali

AU - Laval, Julie

AU - Schlegel, Patrick

AU - Seitz, Christian

AU - Loretz, Brigitta

AU - Lehr, Claus-Michael

AU - Handgretinger, Rupert

AU - Kormann, Michael S D

PY - 2018/11/13

Y1 - 2018/11/13

N2 - Gene therapy has always been a promising therapeutic approach for Cystic Fibrosis (CF). However, numerous trials using DNA or viral vectors encoding the correct protein resulted in a general low efficacy. In the last years, chemically modified messenger RNA (cmRNA) has been proven to be a highly potent, pulmonary drug. Consequently, we first explored the expression, function and immunogenicity of human (h)CFTR encoded by cmRNAhCFTR in vitro and ex vivo, quantified the expression by flow cytometry, determined its function using a YFP based assay and checked the immune response in human whole blood. Similarly, we examined the function of cmRNAhCFTR in vivo after intratracheal (i.t.) or intravenous (i.v.) injection of the assembled cmRNAhCFTR together with Chitosan-coated PLGA (poly-D, L-lactide-co-glycolide 75:25 (Resomer RG 752 H)) nanoparticles (NPs) by FlexiVent. The amount of expression of human hCFTR encoded by cmRNAhCFTR was quantified by hCFTR ELISA, and cmRNAhCFTR values were assessed by RT-qPCR. Thereby, we observed a significant improvement of lung function, especially in regards to FEV0.1, suggesting NP-cmRNAhCFTR as promising therapeutic option for CF patients independent of their CFTR genotype.

AB - Gene therapy has always been a promising therapeutic approach for Cystic Fibrosis (CF). However, numerous trials using DNA or viral vectors encoding the correct protein resulted in a general low efficacy. In the last years, chemically modified messenger RNA (cmRNA) has been proven to be a highly potent, pulmonary drug. Consequently, we first explored the expression, function and immunogenicity of human (h)CFTR encoded by cmRNAhCFTR in vitro and ex vivo, quantified the expression by flow cytometry, determined its function using a YFP based assay and checked the immune response in human whole blood. Similarly, we examined the function of cmRNAhCFTR in vivo after intratracheal (i.t.) or intravenous (i.v.) injection of the assembled cmRNAhCFTR together with Chitosan-coated PLGA (poly-D, L-lactide-co-glycolide 75:25 (Resomer RG 752 H)) nanoparticles (NPs) by FlexiVent. The amount of expression of human hCFTR encoded by cmRNAhCFTR was quantified by hCFTR ELISA, and cmRNAhCFTR values were assessed by RT-qPCR. Thereby, we observed a significant improvement of lung function, especially in regards to FEV0.1, suggesting NP-cmRNAhCFTR as promising therapeutic option for CF patients independent of their CFTR genotype.

U2 - 10.1038/s41598-018-34960-0

DO - 10.1038/s41598-018-34960-0

M3 - Article

C2 - 30425265

VL - 8

SP - 16776

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

ER -